Potential gut-brain mechanisms behind adverse mental health outcomes of bariatric surgery.
Appetite
/ physiology
Bariatric Surgery
/ adverse effects
Brain
/ physiology
Cell Communication
/ physiology
Diabetes Mellitus, Type 2
/ epidemiology
Gastrointestinal Hormones
/ physiology
Humans
Intestines
/ physiology
Mental Disorders
/ epidemiology
Neurosecretory Systems
/ physiology
Obesity
/ epidemiology
Treatment Outcome
Journal
Nature reviews. Endocrinology
ISSN: 1759-5037
Titre abrégé: Nat Rev Endocrinol
Pays: England
ID NLM: 101500078
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
accepted:
03
06
2021
pubmed:
16
7
2021
medline:
24
9
2021
entrez:
15
7
2021
Statut:
ppublish
Résumé
Bariatric surgery induces sustained weight loss and metabolic benefits via notable effects on the gut-brain axis that lead to alterations in the neuroendocrine regulation of appetite and glycaemia. However, in a subset of patients, bariatric surgery is associated with adverse effects on mental health, including increased risk of suicide or self-harm as well as the emergence of depression and substance use disorders. The contributing factors behind these adverse effects are not well understood. Accumulating evidence indicates that there are important links between gut-derived hormones, microbial and bile acid profiles, and disorders of mood and substance use, which warrant further exploration in the context of changes in gut-brain signalling after bariatric surgery. Understanding the basis of these adverse effects is essential in order to optimize the health and well-being of people undergoing treatment for obesity.
Identifiants
pubmed: 34262156
doi: 10.1038/s41574-021-00520-2
pii: 10.1038/s41574-021-00520-2
doi:
Substances chimiques
Gastrointestinal Hormones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
549-559Informations de copyright
© 2021. Springer Nature Limited.
Références
Sjostrom, L. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683–2693 (2004).
pubmed: 15616203
doi: 10.1056/NEJMoa035622
Sjostrom, L. et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357, 741–752 (2007).
pubmed: 17715408
doi: 10.1056/NEJMoa066254
Evers, S. S., Sandoval, D. A. & Seeley, R. J. The physiology and molecular underpinnings of the effects of bariatric surgery on obesity and diabetes. Annu. Rev. Physiol. 79, 313–334 (2017).
pubmed: 27912678
doi: 10.1146/annurev-physiol-022516-034423
Miras, A. D. & le Roux, C. W. Mechanisms underlying weight loss after bariatric surgery. Nat. Rev. Gastroenterol. Hepatol. 10, 575–584 (2013).
pubmed: 23835488
doi: 10.1038/nrgastro.2013.119
Castaneda, D., Popov, V. B., Wander, P. & Thompson, C. C. Risk of suicide and self-harm is increased after bariatric surgery — a systematic review and meta-analysis. Obes. Surg. 29, 322–333 (2019).
pubmed: 30343409
doi: 10.1007/s11695-018-3493-4
Backman, O., Stockeld, D., Rasmussen, F., Naslund, E. & Marsk, R. Alcohol and substance abuse, depression and suicide attempts after Roux-en-Y gastric bypass surgery. Br. J. Surg. 103, 1336–1342 (2016).
pubmed: 27467694
doi: 10.1002/bjs.10258
Huang, T. T. et al. Current understanding of gut microbiota in mood disorders: an update of human studies. Front. Genet. 10, 98 (2019).
pubmed: 30838027
pmcid: 6389720
doi: 10.3389/fgene.2019.00098
Ramos, A. et al. Fifth IFSO Global Registry Report. https://www.ifso.com/pdf/5th-ifso-global-registry-report-september-2019.pdf (2019).
Okano-Matsumoto, S., McRoberts, J. A., Tache, Y. & Adelson, D. W. Electrophysiological evidence for distinct vagal pathways mediating CCK-evoked motor effects in the proximal versus distal stomach. J. Physiol. 589, 371–393 (2011).
pubmed: 21078593
doi: 10.1113/jphysiol.2010.196832
Meek, C. L., Lewis, H. B., Reimann, F., Gribble, F. M. & Park, A. J. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 77, 28–37 (2016).
pubmed: 26344355
doi: 10.1016/j.peptides.2015.08.013
Morinigo, R. et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J. Clin. Endocrinol. Metab. 91, 1735–1740 (2006).
pubmed: 16478824
doi: 10.1210/jc.2005-0904
McCarty, T. R., Jirapinyo, P. & Thompson, C. C. Effect of sleeve gastrectomy on ghrelin, GLP-1, PYY, and GIP gut hormones: a systematic review and meta-analysis. Ann. Surg. 272, 72–80 (2020).
pubmed: 31592891
doi: 10.1097/SLA.0000000000003614
Xu, H.-C. et al. Systematic review and meta-analysis of the change in ghrelin levels after roux-en-Y gastric bypass. Obes. Surg. 29, 1343–1351 (2019).
pubmed: 30684171
doi: 10.1007/s11695-018-03686-3
Chambers, A. P. et al. The effects of vertical sleeve gastrectomy in rodents are ghrelin independent. Gastroenterology 144, 50–52.e5 (2013).
pubmed: 22995675
doi: 10.1053/j.gastro.2012.09.009
Hunt, K. F. et al. Differences in regional brain responses to food ingestion after roux-en-Y gastric bypass and the role of gut peptides: a neuroimaging study. Diabetes Care 39, 1787–1795 (2016).
pubmed: 27660120
doi: 10.2337/dc15-2721
le Roux, C. W. et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann. Surg. 246, 780–785 (2007). This study evaluates the time course and contribution of gut-derived satiety hormones on appetite regulation after RYGB.
pubmed: 17968169
doi: 10.1097/SLA.0b013e3180caa3e3
Yoshino, M. et al. Effects of diet versus gastric bypass on metabolic function in diabetes. N. Engl. J. Med. 383, 721–732 (2020).
pubmed: 32813948
pmcid: 7456610
doi: 10.1056/NEJMoa2003697
Dirksen, C. et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 55, 1890–1901 (2012).
pubmed: 22538359
doi: 10.1007/s00125-012-2556-7
Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
pubmed: 20203603
pmcid: 3779803
doi: 10.1038/nature08821
Ley, R. E. et al. Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. USA 102, 11070–11075 (2005).
pubmed: 16033867
pmcid: 1176910
doi: 10.1073/pnas.0504978102
Schwiertz, A. et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 18, 190–195 (2010).
pubmed: 19498350
doi: 10.1038/oby.2009.167
Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541–546 (2013).
pubmed: 23985870
doi: 10.1038/nature12506
Canfora, E. E., Meex, R. C. R., Venema, K. & Blaak, E. E. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat. Rev. Endocrinol. 15, 261–273 (2019).
pubmed: 30670819
doi: 10.1038/s41574-019-0156-z
Tremaroli, V. et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 22, 228–238 (2015). This paper shows long-term alterations in gut microbial composition and function after bariatric surgery and their potential to modulate host metabolism.
pubmed: 26244932
pmcid: 4537510
doi: 10.1016/j.cmet.2015.07.009
Liou, A. P. et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci. Transl. Med. 5, 178ra141 (2013).
doi: 10.1126/scitranslmed.3005687
Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137–174 (2003).
pubmed: 12543708
doi: 10.1146/annurev.biochem.72.121801.161712
Staudinger, J. L. et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl Acad. Sci. USA 98, 3369–3374 (2001).
pubmed: 11248085
pmcid: 30660
doi: 10.1073/pnas.051551698
Makishima, M. et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296, 1313–1316 (2002).
pubmed: 12016314
doi: 10.1126/science.1070477
Steinert, R. E. et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity 21, E660–E668 (2013).
pubmed: 23804517
doi: 10.1002/oby.20522
Jorgensen, N. B. et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. J. Clin. Endocrinol. Metab. 100, E396–E406 (2015).
pubmed: 25536209
doi: 10.1210/jc.2014-1658
Chen, Y., Lu, J., Nemati, R., Plank, L. D. & Murphy, R. Acute changes of bile acids and FGF19 after sleeve gastrectomy and roux-en-Y gastric bypass. Obes. Surg. 29, 3605–3621 (2019).
pubmed: 31273649
doi: 10.1007/s11695-019-04040-x
Albaugh, V. L. et al. Early increases in bile acids post roux-en-Y gastric bypass are driven by insulin-sensitizing, secondary bile acids. J. Clin. Endocrinol. Metab. 100, E1225–E1233 (2015).
pubmed: 26196952
pmcid: 4570157
doi: 10.1210/jc.2015-2467
Nemati, R. et al. Increased bile acids and FGF19 after sleeve gastrectomy and roux-en-Y gastric bypass correlate with improvement in type 2 diabetes in a randomized trial. Obes. Surg. 28, 2672–2686 (2018).
pubmed: 29987678
doi: 10.1007/s11695-018-3216-x
Albaugh, V. L. et al. Role of bile acids and GLP-1 in mediating the metabolic improvements of bariatric surgery. Gastroenterology 156, 1041–1051.e4 (2019).
pubmed: 30445014
doi: 10.1053/j.gastro.2018.11.017
Kalarchian, M. A. et al. Mental disorders and weight change in a prospective study of bariatric surgery patients: 7 years of follow-up. Surg. Obes. Relat. Dis. 15, 739–748 (2019).
pubmed: 30826244
pmcid: 7045720
doi: 10.1016/j.soard.2019.01.008
Mitchell, J. E. et al. Course of depressive symptoms and treatment in the longitudinal assessment of bariatric surgery (LABS-2) study. Obesity 22, 1799–1806 (2014).
pubmed: 24634371
doi: 10.1002/oby.20738
Mitchell, J. E. et al. Possible risk factors for increased suicide following bariatric surgery. Obesity 21, 665–672 (2013).
pubmed: 23404774
doi: 10.1002/oby.20066
Stammers, L. et al. Identifying stress-related eating in behavioural research: a review. Hormones Behav. 124, 104752 (2020).
doi: 10.1016/j.yhbeh.2020.104752
Lagerros, Y. T., Brandt, L., Hedberg, J., Sundbom, M. & Bodén, R. Suicide, self-harm, and depression after gastric bypass surgery: a nationwide cohort study. Ann. Surg. 265, 235–243 (2017).
pubmed: 27387654
doi: 10.1097/SLA.0000000000001884
Hamad, G. G. et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am. J. Psychiatry 169, 256–263 (2012).
pubmed: 22407114
pmcid: 3583374
doi: 10.1176/appi.ajp.2011.11050719
Neovius, M. et al. Risk of suicide and non-fatal self-harm after bariatric surgery: results from two matched cohort studies. Lancet Diabetes Endocrinol. 6, 197–207 (2018). This article shows an increased risk of suicide and self-harm after bariatric surgery in two separate cohorts, among patients with and without known psychiatric disorders.
pubmed: 29329975
pmcid: 5932484
doi: 10.1016/S2213-8587(17)30437-0
Morgan, D. J. R., Ho, K. M. & Platell, C. Incidence and determinants of mental health service use after bariatric surgery. JAMA Psychiatry 77, 60–67 (2020).
pubmed: 31553420
doi: 10.1001/jamapsychiatry.2019.2741
Knop, J. & Fischer, A. Duodenal ulcer, suicide, psychopathology and alcoholism. Acta Psychiatr. Scand. 63, 346–355 (1981).
pubmed: 7315483
doi: 10.1111/j.1600-0447.1981.tb00683.x
Klarer, M. et al. Gut vagal afferents differentially modulate innate anxiety and learned fear. J. Neurosci. 34, 7067–7076 (2014).
pubmed: 24849343
pmcid: 6608191
doi: 10.1523/JNEUROSCI.0252-14.2014
Lutter, M. et al. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat. Neurosci. 11, 752–753 (2008). Through several experimental approaches, this paper shows a role of ghrelin in defending against anxiety-like and depression-like behaviour.
pubmed: 18552842
pmcid: 2765052
doi: 10.1038/nn.2139
Alvarez-Crespo, M. et al. The amygdala as a neurobiological target for ghrelin in rats: neuroanatomical, electrophysiological and behavioral evidence. PLoS ONE 7, e46321 (2012).
pubmed: 23071554
pmcid: 3468604
doi: 10.1371/journal.pone.0046321
Spencer, S. J. et al. Ghrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety after acute stress. Biol. Psychiatry 72, 457–465 (2012).
pubmed: 22521145
doi: 10.1016/j.biopsych.2012.03.010
Asakawa, A. et al. A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinology 74, 143–147 (2001).
pubmed: 11528215
doi: 10.1159/000054680
Currie, P. J. et al. Ghrelin is an orexigenic peptide and elicits anxiety-like behaviors following administration into discrete regions of the hypothalamus. Behav. Brain Res. 226, 96–105 (2012).
pubmed: 21907737
doi: 10.1016/j.bbr.2011.08.037
Hansson, C. et al. Central administration of ghrelin alters emotional responses in rats: behavioural, electrophysiological and molecular evidence. Neuroscience 180, 201–211 (2011).
pubmed: 21303683
doi: 10.1016/j.neuroscience.2011.02.002
Carlini, V. P. et al. Acute ghrelin administration reverses depressive-like behavior induced by bilateral olfactory bulbectomy in mice. Peptides 35, 160–165 (2012).
pubmed: 22525660
doi: 10.1016/j.peptides.2012.03.031
Huang, H. J. et al. Ghrelin alleviates anxiety- and depression-like behaviors induced by chronic unpredictable mild stress in rodents. Behav. Brain Res. 326, 33–43 (2017).
pubmed: 28245976
doi: 10.1016/j.bbr.2017.02.040
Schmid, D. A. et al. Ghrelin stimulates appetite, imagination of food, GH, ACTH, and cortisol, but does not affect leptin in normal controls. Neuropsychopharmacology 30, 1187–1192 (2005).
pubmed: 15688086
doi: 10.1038/sj.npp.1300670
Kluge, M. et al. Effects of ghrelin on psychopathology, sleep and secretion of cortisol and growth hormone in patients with major depression. J. Psychiatr. Res. 45, 421–426 (2011).
pubmed: 20888580
doi: 10.1016/j.jpsychires.2010.09.002
Lundholm, K. et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 116, 2044–2052 (2010).
pubmed: 20186829
doi: 10.1002/cncr.24917
Cain, B. M. et al. Distribution and colocalization of cholecystokinin with the prohormone convertase enzymes PC1, PC2, and PC5 in rat brain. J. Comp. Neurol. 467, 307–325 (2003).
pubmed: 14608596
doi: 10.1002/cne.10924
Rezayat, M., Roohbakhsh, A., Zarrindast, M. R., Massoudi, R. & Djahanguiri, B. Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety. Physiol. Behav. 84, 775–782 (2005).
pubmed: 15885255
doi: 10.1016/j.physbeh.2005.03.002
Hernando, F., Fuentes, J. A., Roques, B. P. & Ruiz-Gayo, M. The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. Eur. J. Pharmacol. 261, 257–263 (1994).
pubmed: 7813546
doi: 10.1016/0014-2999(94)90115-5
Chen, Q. et al. Bi-directional effect of cholecystokinin receptor-2 overexpression on stress-triggered fear memory and anxiety in the mouse. PLoS ONE 5, e15999 (2010).
pubmed: 21209861
pmcid: 3012733
doi: 10.1371/journal.pone.0015999
Becker, C. et al. Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin. Mol. Psychiatry 13, 1079–1092 (2008).
pubmed: 17893702
doi: 10.1038/sj.mp.4002097
Bradwejn, J., Koszycki, D. & Meterissian, G. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can. J. Psychiatry 35, 83–85 (1990).
pubmed: 2180549
doi: 10.1177/070674379003500115
van Megen, H. J., Westenberg, H. G., den Boer, J. A., Haigh, J. R. & Traub, M. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology 114, 449–455 (1994).
pubmed: 7855203
doi: 10.1007/BF02249335
Bradwejn, J. et al. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psychiatry 51, 486–493 (1994).
pubmed: 8192551
doi: 10.1001/archpsyc.1994.03950060050005
Adams, J. B. et al. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 15, 428–434 (1995).
pubmed: 8748432
doi: 10.1097/00004714-199512000-00007
Kramer, M. S. et al. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol. Psychiatry 37, 462–466 (1995).
pubmed: 7786960
doi: 10.1016/0006-3223(94)00190-E
de Montigny, C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch. Gen. Psychiatry 46, 511–517 (1989).
pubmed: 2730276
doi: 10.1001/archpsyc.1989.01810060031006
Secher, A. et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J. Clin. Invest. 124, 4473–4488 (2014).
pubmed: 25202980
pmcid: 4215190
doi: 10.1172/JCI75276
Alvarez, E. et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. 92, 798–806 (2005).
pubmed: 15686481
doi: 10.1111/j.1471-4159.2004.02914.x
Rinaman, L. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am. J. Physiol. 277, R582–R590 (1999).
pubmed: 10444567
Kinzig, K. P. et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J. Neurosci. 23, 6163–6170 (2003).
pubmed: 12867498
pmcid: 6740553
doi: 10.1523/JNEUROSCI.23-15-06163.2003
Isacson, R. et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. 650, 249–255 (2011).
pubmed: 20951130
doi: 10.1016/j.ejphar.2010.10.008
Anderberg, R. H. et al. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology 65, 54–66 (2016).
pubmed: 26724568
doi: 10.1016/j.psyneuen.2015.11.021
Strawn, J. R., D’Alessio, D. A., Keck, P. E. Jr. & Seeley, R. J. Failure of glucagon-like peptide-1 to induce panic attacks or anxiety in patients with panic disorder. J. Psychiatr. Res. 42, 787–789 (2008).
pubmed: 17888452
doi: 10.1016/j.jpsychires.2007.08.007
van Bloemendaal, L. et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 63, 4186–4196 (2014).
pubmed: 25071023
doi: 10.2337/db14-0849
Bode, B. W. et al. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes. Metab. 12, 604–612 (2010).
pubmed: 20590735
pmcid: 2901519
doi: 10.1111/j.1463-1326.2010.01196.x
Kahal, H., Kilpatrick, E., Rigby, A., Coady, A. & Atkin, S. The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls. Gynecol. Endocrinol. 35, 142–145 (2019).
pubmed: 30599799
doi: 10.1080/09513590.2018.1505848
Grant, P., Lipscomb, D. & Quin, J. Psychological and quality of life changes in patients using GLP-1 analogues. J. Diabetes Complications 25, 244–246 (2011).
pubmed: 21601480
doi: 10.1016/j.jdiacomp.2011.03.002
Adrian, T. E. et al. Neuropeptide Y distribution in human brain. Nature 306, 584–586 (1983).
pubmed: 6358901
doi: 10.1038/306584a0
Redrobe, J. P., Dumont, Y., Fournier, A. & Quirion, R. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 26, 615–624 (2002).
pubmed: 11927186
doi: 10.1016/S0893-133X(01)00403-1
Karl, T., Burne, T. H. J. & Herzog, H. Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behav. Brain Res. 167, 87–93 (2006).
pubmed: 16203045
doi: 10.1016/j.bbr.2005.08.019
Morales-Medina, J. C. et al. Role of neuropeptide Y Y
pubmed: 21803058
doi: 10.1016/j.neuropharm.2011.06.030
Yamada, C., Mogami, S., Kanno, H. & Hattori, T. Peptide YY causes apathy-like behavior via the dopamine D2 receptor in repeated water-immersed mice. Mol. Neurobiol. 55, 7555–7566 (2018).
pubmed: 29429048
pmcid: 6096978
doi: 10.1007/s12035-018-0931-1
Painsipp, E. et al. Reduced anxiety-like and depression-related behavior in neuropeptide Y Y4 receptor knockout mice. Genes Brain Behav. 7, 532–542 (2008).
pubmed: 18221379
pmcid: 4359911
doi: 10.1111/j.1601-183X.2008.00389.x
Asakawa, A. et al. Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 20, 1445–1448 (1999).
pubmed: 10698120
doi: 10.1016/S0196-9781(99)00155-2
Zhou, Z. et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 452, 997–1001 (2008).
pubmed: 18385673
pmcid: 2715959
doi: 10.1038/nature06858
Domschke, K. et al. Neuropeptide Y (NPY) gene: Impact on emotional processing and treatment response in anxious depression. Eur. Neuropsychopharmacol. 20, 301–309 (2010).
pubmed: 19854625
doi: 10.1016/j.euroneuro.2009.09.006
Kristenssson, E. et al. Acute psychological stress raises plasma ghrelin in the rat. Regul. Pept. 134, 114–117 (2006).
pubmed: 16540188
doi: 10.1016/j.regpep.2006.02.003
Lambert, E. et al. Ghrelin modulates sympathetic nervous system activity and stress response in lean and overweight men. Hypertension 58, 43–50 (2011).
pubmed: 21502567
doi: 10.1161/HYPERTENSIONAHA.111.171025
Langer, F. B. et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes. Surg. 15, 1024–1029 (2005).
pubmed: 16105401
doi: 10.1381/0960892054621125
Diaz Heijtz, R. et al. Normal gut microbiota modulates brain development and behavior. Proc. Natl Acad. Sci. USA 108, 3047–3052 (2011).
pubmed: 21282636
doi: 10.1073/pnas.1010529108
Naseribafrouei, A. et al. Correlation between the human fecal microbiota and depression. Neurogastroenterol. Motil. 26, 1155–1162 (2014).
pubmed: 24888394
doi: 10.1111/nmo.12378
Jiang, H. Y. et al. Altered gut microbiota profile in patients with generalized anxiety disorder. J. Psychiatr. Res. 104, 130–136 (2018).
pubmed: 30029052
doi: 10.1016/j.jpsychires.2018.07.007
Zheng, P. et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol. Psychiatry 21, 786–796 (2016).
pubmed: 27067014
doi: 10.1038/mp.2016.44
Li, J. et al. Short term intrarectal administration of sodium propionate induces antidepressant-like effects in rats exposed to chronic unpredictable mild stress. Front. Psychiatry 9, 454 (2018).
pubmed: 30319461
pmcid: 6170646
doi: 10.3389/fpsyt.2018.00454
Kelly, J. R. et al. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. J. Psychiatr. Res. 82, 109–118 (2016).
pubmed: 27491067
doi: 10.1016/j.jpsychires.2016.07.019
Kelly, J. R. et al. Lost in translation? The potential psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy male subjects. Brain Behav. Immun. 61, 50–59 (2017).
pubmed: 27865949
doi: 10.1016/j.bbi.2016.11.018
Messaoudi, M. et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br. J. Nutr. 105, 755–764 (2011).
pubmed: 20974015
doi: 10.1017/S0007114510004319
Pinto-Sanchez, M. I. et al. Probiotic bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology 153, 448–459.e8 (2017).
pubmed: 28483500
doi: 10.1053/j.gastro.2017.05.003
Valles-Colomer, M. et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat. Microbiol. 4, 623–632 (2019).
pubmed: 30718848
doi: 10.1038/s41564-018-0337-x
Yamawaki, Y. et al. Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus. World J. Biol. Psychiatry 13, 458–467 (2012).
pubmed: 21812623
doi: 10.3109/15622975.2011.585663
Sun, J. et al. Antidepressant-like effects of sodium butyrate and its possible mechanisms of action in mice exposed to chronic unpredictable mild stress. Neurosci. Lett. 618, 159–166 (2016).
pubmed: 26957230
doi: 10.1016/j.neulet.2016.03.003
Huang, C. et al. Identification of functional farnesoid X receptors in brain neurons. FEBS Lett. 590, 3233–3242 (2016).
pubmed: 27545319
doi: 10.1002/1873-3468.12373
Huang, F. et al. Deletion of mouse FXR gene disturbs multiple neurotransmitter systems and alters neurobehavior. Front. Behav. Neurosci. 9, 70 (2015).
pubmed: 25870546
pmcid: 4378301
Chen, W. G., Zheng, J. X., Xu, X., Hu, Y. M. & Ma, Y. M. Hippocampal FXR plays a role in the pathogenesis of depression: a preliminary study based on lentiviral gene modulation. Psychiatry Res. 264, 374–379 (2018).
pubmed: 29677620
doi: 10.1016/j.psychres.2018.04.025
Lu, X. et al. Tauroursodeoxycholic acid produces antidepressant-like effects in a chronic unpredictable stress model of depression via attenuation of neuroinflammation, oxido-nitrosative stress, and endoplasmic reticulum stress. Fundam. Clin. Pharmacol. 32, 363–377 (2018).
pubmed: 29578616
doi: 10.1111/fcp.12367
Şen, O., Ünübol, H., Türkçapar, A. G. & Yerdel, M. A. Risk of alcohol use disorder after sleeve gastrectomy. J. Laparoendosc. Adv. Surg. Tech. A 31, 24–28 (2020).
pubmed: 32525729
doi: 10.1089/lap.2020.0306
Li, L. & Wu, L. T. Substance use after bariatric surgery: a review. J. Psychiatr. Res. 76, 16–29 (2016).
pubmed: 26871733
pmcid: 4789154
doi: 10.1016/j.jpsychires.2016.01.009
Raebel, M. A. et al. Chronic use of opioid medications before and after bariatric surgery. JAMA 310, 1369–1376 (2013). A retrospective cohort study of 11,719 individuals that shows increased opioid use following bariatric surgery.
pubmed: 24084922
doi: 10.1001/jama.2013.278344
Bak, M., Seibold-Simpson, S. M. & Darling, R. The potential for cross-addiction in post-bariatric surgery patients: considerations for primary care nurse practitioners. J. Am. Assoc. Nurse Pract. 28, 675–682 (2016).
pubmed: 27400415
doi: 10.1002/2327-6924.12390
McFadden, K. M. Cross-addiction: from morbid obesity to substance abuse. Bariatr. Nurs. Surg. Patient Care 5, 145–178 (2010).
doi: 10.1089/bar.2010.9922
King, W. C. et al. Prevalence of alcohol use disorders before and after bariatric surgery. JAMA 307, 2516–2525 (2012). The first large multicentre observational study showing increased alcohol use and incidence of AUD in the second year following bariatric surgery as compared with the year before or 1 year after.
pubmed: 22710289
pmcid: 3682834
doi: 10.1001/jama.2012.6147
Hajnal, A. et al. Alcohol reward is increased after Roux-en-Y gastric bypass in dietary obese rats with differential effects following ghrelin antagonism. PLoS ONE 7, e49121 (2012).
pubmed: 23145091
pmcid: 3492295
doi: 10.1371/journal.pone.0049121
Sirohi, S., Richardson, B. D., Lugo, J. M., Rossi, D. J. & Davis, J. F. Impact of Roux-en-Y gastric bypass surgery on appetite, alcohol intake behaviors, and midbrain ghrelin signaling in the rat. Obesity 25, 1228–1236 (2017).
pubmed: 28500684
doi: 10.1002/oby.21839
King, W. C. et al. Alcohol and other substance use after bariatric surgery: prospective evidence from a U.S. multicenter cohort study. Surg. Obes. Relat. Dis. 13, 1392–1402 (2017).
pubmed: 28528115
pmcid: 5568472
doi: 10.1016/j.soard.2017.03.021
Orellana, E. R., Jamis, C., Horvath, N. & Hajnal, A. Effect of vertical sleeve gastrectomy on alcohol consumption and preferences in dietary obese rats and mice: a plausible role for altered ghrelin signaling. Brain Res. Bull. 138, 26–36 (2018).
pubmed: 28802901
doi: 10.1016/j.brainresbull.2017.08.004
Saules, K. K. et al. Bariatric surgery history among substance abuse treatment patients: prevalence and associated features. Surg. Obes. Relat. Dis. 6, 615–621 (2010).
pubmed: 20207591
doi: 10.1016/j.soard.2009.12.008
Biegler, J. M., Freet, C. S., Horvath, N., Rogers, A. M. & Hajnal, A. Increased intravenous morphine self-administration following Roux-en-Y gastric bypass in dietary obese rats. Brain Res. Bull. 123, 47–52 (2016).
pubmed: 26304761
doi: 10.1016/j.brainresbull.2015.08.003
Wiedemann, A. A., Saules, K. K. & Ivezaj, V. Emergence of new onset substance use disorders among post-weight loss surgery patients. Clin. Obes. 3, 194–201 (2013).
pubmed: 25586736
doi: 10.1111/cob.12034
Ivezaj, V., Saules, K. K. & Wiedemann, A. A. “I didn’t see this coming”: why are postbariatric patients in substance abuse treatment? Patients’ perceptions of etiology and future recommendations. Obes. Surg. 22, 1308–1314 (2012).
pubmed: 22661046
doi: 10.1007/s11695-012-0668-2
Sketriene, D., Ch’ng, S. S. & Brown, R. M. in Anti-Obesity Drug Discovery and Development Vol. 5 (eds Atta-ur-Rahman & Choudhary, M. I.) Ch. 1, 1–57 (Bentham Science Publishers, 2020).
Brown, R. M. et al. Addiction-like synaptic impairments in diet-induced obesity. Biol. Psychiatry 81, 797–806 (2017).
pubmed: 26826876
doi: 10.1016/j.biopsych.2015.11.019
Yoder, R., MacNeela, P., Conway, R. & Heary, C. How do individuals develop alcohol use disorder after bariatric surgery? A grounded theory exploration. Obes. Surg. 28, 717–724 (2018).
pubmed: 29032488
doi: 10.1007/s11695-017-2936-7
Hardman, C. A. & Christiansen, P. Psychological issues and alcohol misuse following bariatric surgery. Nat. Rev. Endocrinol. 14, 377–378 (2018).
pubmed: 29622789
doi: 10.1038/s41574-018-0006-4
Acevedo, M. B. et al. Sleeve gastrectomy surgery: when 2 alcoholic drinks are converted to 4. Surg. Obes. Relat. Dis. 14, 277–283 (2018).
pubmed: 29305304
doi: 10.1016/j.soard.2017.11.010
Hagedorn, J. C., Encarnacion, B., Brat, G. A. & Morton, J. M. Does gastric bypass alter alcohol metabolism? Surg. Obes. Relat. Dis. 3, 543–548 (2007).
pubmed: 17903777
doi: 10.1016/j.soard.2007.07.003
Lloret-Linares, C. et al. Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. Clin. Pharmacokinet. 53, 919–930 (2014).
pubmed: 25141973
doi: 10.1007/s40262-014-0163-0
Strommen, M., Helland, A., Kulseng, B. & Spigset, O. Bioavailability of methadone after sleeve gastrectomy: a planned case observation. Clin. Ther. 38, 1532–1536 (2016).
pubmed: 27181614
doi: 10.1016/j.clinthera.2016.04.033
Whitfield, J. B. et al. Variation in alcohol pharmacokinetics as a risk factor for alcohol dependence. Alcohol. Clin. Exp. Res. 25, 1257–1263 (2001).
pubmed: 11584143
doi: 10.1111/j.1530-0277.2001.tb02345.x
Polston, J. E. et al. Roux-en-Y gastric bypass increases intravenous ethanol self-administration in dietary obese rats. PLoS ONE 8, e83741 (2013).
pubmed: 24391816
pmcid: 3877092
doi: 10.1371/journal.pone.0083741
Davis, J. F. et al. Roux en Y gastric bypass increases ethanol intake in the rat. Obes. Surg. 23, 920–930 (2013).
pubmed: 23440511
pmcid: 3970194
doi: 10.1007/s11695-013-0884-4
Thiele, T. E., Sparta, D. R., Hayes, D. M. & Fee, J. R. A role for neuropeptide Y in neurobiological responses to ethanol and drugs of abuse. Neuropeptides 38, 235–243 (2004).
pubmed: 15337375
doi: 10.1016/j.npep.2004.04.005
Davis, J. F. et al. Gastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats. Biol. Psychiatry 72, 354–360 (2012).
pubmed: 22444202
doi: 10.1016/j.biopsych.2012.01.035
Skibicka, K. P., Hansson, C., Alvarez-Crespo, M., Friberg, P. A. & Dickson, S. L. Ghrelin directly targets the ventral tegmental area to increase food motivation. Neuroscience 180, 129–137 (2011).
pubmed: 21335062
doi: 10.1016/j.neuroscience.2011.02.016
Jerlhag, E. et al. Requirement of central ghrelin signaling for alcohol reward. Proc. Natl Acad. Sci. USA 106, 11318–11323 (2009). This article shows the involvement of central ghrelin signalling in the rewarding effects of alcohol.
pubmed: 19564604
pmcid: 2703665
doi: 10.1073/pnas.0812809106
Jerlhag, E., Ivanoff, L., Vater, A. & Engel, J. A. Peripherally circulating ghrelin does not mediate alcohol-induced reward and alcohol intake in rodents. Alcohol. Clin. Exp. Res. 38, 959–968 (2014).
pubmed: 24428428
pmcid: 4112802
doi: 10.1111/acer.12337
Wee, C. C. et al. High-risk alcohol use after weight loss surgery. Surg. Obes. Relat. Dis. 10, 508–513 (2014).
pubmed: 24680762
pmcid: 4065843
doi: 10.1016/j.soard.2013.12.014
Shirazi, R. H., Dickson, S. L. & Skibicka, K. P. Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward. PLoS ONE 8, e61965 (2013).
pubmed: 23613987
pmcid: 3628574
doi: 10.1371/journal.pone.0061965
Meckel, K. R. & Kiraly, D. D. A potential role for the gut microbiome in substance use disorders. Psychopharmacology 236, 1513–1530 (2019).
pubmed: 30982128
pmcid: 6599482
doi: 10.1007/s00213-019-05232-0
Jadhav, K. S. et al. Gut microbiome correlates with altered striatal dopamine receptor expression in a model of compulsive alcohol seeking. Neuropharmacology 141, 249–259 (2018).
pubmed: 30172845
doi: 10.1016/j.neuropharm.2018.08.026
Wang, F. et al. Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model. Sci. Rep. 8, 3596 (2018).
pubmed: 29483538
pmcid: 5827657
doi: 10.1038/s41598-018-21915-8
Reddy, I. A. et al. Bile diversion, a bariatric surgery, and bile acid signaling reduce central cocaine reward. PLoS Biol. 16, e2006682 (2018).
pubmed: 30048457
pmcid: 6061973
doi: 10.1371/journal.pbio.2006682
Docherty, N. G. & le Roux, C. W. Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. Nat. Rev. Nephrol. 16, 709–720 (2020).
pubmed: 32778788